iBio Provides Update on IBIO-201 COVID-19 Vaccine Program
August 10, 2020 07:15 ET
|
iBio, Inc.
NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology corporation and biologics contract manufacturing organization, today provided...
iBio to be Added to the Russell 2000® and Russell 3000® Indexes
June 26, 2020 06:45 ET
|
iBio, Inc.
NEW YORK, June 26, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics innovator and contract manufacturing organization, today announced that it will be...
iBio Selected by IBM Watson Health for the use of IBM Clinical Development Solution at No Cost to help Support clinical COVID-19 Vaccine Candidates
June 24, 2020 06:45 ET
|
iBio, Inc.
NEW YORK, June 24, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced that...
iBio Announces Second COVID-19 Vaccine Program
June 04, 2020 07:00 ET
|
iBio, Inc.
- IBIO-201, a subunit vaccine combining SARS-CoV-2 spike protein antigens with the Company’s proprietary LicKM booster technology, advances to preclinical immunization studies with the potential for...
iBio Estimates ~500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility™
April 27, 2020 16:15 ET
|
iBio, Inc.
- Company Expands Involvement in the Manufacturing USA® Network, Joining the National Institute for Innovation in Manufacturing Biopharmaceuticals - NEW YORK , April 27, 2020 (GLOBE NEWSWIRE) --...
iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute
April 09, 2020 07:30 ET
|
iBio, Inc.
NEW YORK, April 09, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology innovator, today announced...
iBio Supporting AzarGen Biotechnologies’ Development of a Rituximab Biosimilar
March 26, 2020 16:20 ET
|
iBio, Inc.
NEW YORK, March 26, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into a second Statement of Work under its Master Joint...
iBio Announces Advancement of COVID-19 Vaccine Program
March 26, 2020 07:30 ET
|
iBio, Inc.
NEW YORK, March 26, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced...
iBio Joins the Alliance for Biosecurity
March 20, 2020 07:30 ET
|
iBio, Inc.
NEW YORK, March 20, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced...
iBio Announces Development of Proprietary COVID-19 Vaccine Candidates
March 18, 2020 08:00 ET
|
iBio, Inc.
NEW YORK, March 18, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced its...